Clinical analysis of gemcitabine combined with nedaplatin for sequential chemoradiotherapy in treatment of lung squamous cell carcinoma

Objective To investigate the clinical application of gemcitabine combined with nedaplatin for sequential chemoradiotherapy in the treatment of lung squamous cell carcinoma. Methods 74 selected patients with lung squamous cell carcinoma were divided into experimental group (n=37) and control group (n=37). Control group was treated with chemotherapy, experimental group was treated with chemotherapy and three dimensional conformal radiation therapy.Chemotherapy regimen took 21 days for one cycle, at the same time of first cycle of chemotherapy, three dimensional conformal radiotherapy was used for primary lesions.The clinical efficacy, improvement of life quality and adverse reactions were observed. Results The patients with lung squamous cell carcinoma all completed the treatment plan.The total effective rate of experimental group was 54.1%, and the disease control rate was 81.1%, which was superior to the control group with gemcitabine combined with nedaplatin chemotherapy.The effective rate of improvement of life quality in experimental group and control group was 73.0%, 64.9% respectively, there was no significant difference between the two groups (P>0.05). The main adverse reactions of the two groups were the depression of white blood cell, platelet and hemoglobin and nausea and vomittin, gradiation pneumonitis and oesophagitis in experimental group were light and could be tolerated after symptomatic treatment. Conclusions Gemcitabine combined with nedaplatin for sequential chemoradiotherapy has remarkable clinical efficacy and less adverse reactions.It is worthy of clinical research and popularization. Key words: Lung squamous cell carcinoma; Gemcitabine; Nedaplatin; Chemoradiotherapy